Searchable abstracts of presentations at key conferences in endocrinology

ea0056p439 | Diabetes complications | ECE2018

Hyperlipidemia during gestational diabetes: maternal and offspring complications

Herrera-Martinez Aura D. , Palomares Ortega Rafael , Bahamondes Opazo Rodrigo , Moreno Moreno Paloma , Galvez Moreno Maria A.

Lipid profile suffers adaptive changes during pregnancy due to estrogen stimulation and insulin resistance. Several relations have been suggested between maternal lipid profile, glucose tolerance, endothelial cell dysfunction and long-term cardiovascular risk; the effects of maternal lipid profile metabolism in fetal growth are also inconclusive. Since a regular evaluation and follow-up of lipid profile during pregnancy has not been stablished yet, we aimed to evaluate the inc...

ea0056p484 | Diabetes therapy | ECE2018

Dapagliflozin after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objective: To evaluate the efficacy of dapagliflozin for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with tipo 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and dapagliflozin is added. Variables analyzed baseline and at 6 months after treatme...

ea0056p485 | Diabetes therapy | ECE2018

Canagliflozin after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Alhambra-Exposito Maria Rosa , Munoz-Jimenez Concepcion , Galvez-Moreno Maria Angeles

Objective: To evaluate the efficacy of canagliflozin 100 mg for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with type 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and canagliflozin 100 mg is added. Variables analyzed baseline and at 6 months...

ea0056p486 | Diabetes therapy | ECE2018

Inhibitors SGLT2 after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objetive: The change of treatment of liraglutide 1.8 mg to dapagliflozin or canaglifonzin 100 mg in patients with optimal glycemic control and stabilization weight loss, achieves progression in weight loss and improves the metabolic control of the patient with tipo 2 diabetes (DM-2). Our objective is to evaluate if there are differences in metabolic control and progression of weight loss in patients treated with canagliflozin 100 mg or dapagliflozin.Pati...

ea0081p365 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Flash glucose monitoring in patients with DM3c

Rebollo-Roman Angel , Leon-Idougourram Soraya , Manuel Alzas Teomiro Carlos , Moreno-Moreno Paloma , Angeles Galvez Moreno Maria

Objective: Flash glucose monitoring (FGM) allows non-invasive glucose level assessment. Since November 2020 the use of this system is subsidized in patients with type 3c diabetes (DM3c) Our objective was to describe the characteristics of these patients and their glycemic control expressed as times in range.Methods and patients: Observational longitudinal clinical study between January 2021 and December 2021 in patients with DM3c in which FGM implementat...

ea0081p662 | Pituitary and Neuroendocrinology | ECE2022

Inferior petrosal sinus sampling for pituitary neuroendocrine tumors localization in cushing’s disease

Moreno-Moreno Paloma , Rosa Alhambra Exposito Ma , Rebollo-Roman Angel , Herrera-Martinez Aura D. , Angeles Galvez-Moreno Maria

Objective: Cushing’s disease (CD) is the most common cause of hypercortisolism after iatrogenic origin, it represents approximately 70% of patients with endogenous Cushing’s syndrome (CS) and ectopic ACTH secretion (10%). CD is caused by a corticotropin-secreting pituitary neuroendocrine tumor (ACTH-secreting Pit-NETs), 95% of cases as a microadenoma. In ACTH-dependent CS, differential diagnosis between CD and ectopic CS must be established. 40% of CD cases, any tumo...

ea0081ep113 | Adrenal and Cardiovascular Endocrinology | ECE2022

Adrenal venous sampling in patients with hyperaldosteronism

Rebollo-Roman Angel , Serrano Laguna Ma del Carmen , Perez-Montilla Maria-Eugenia , Moreno-Moreno Paloma , Moreno Maria Angeles Galvez

Objective: Adrenal venous sampling (AVP) is a reliable procedure to differentiate if in patients with primary aldosteronism (PA) aldosterone production is unilateral or bilateral and guide the treatment of these patients. Our objective was to describe their characteristics and the outcomes of the AVPs.Methods and patients: Observational longitudinal clinical study between July 2020 and September 2021 in patients who underwent AVP in our Hospital.<p c...

ea0081ep415 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Flash glucose monitoring in patients with type 1 diabetes

Garcia-Ramirez Mireia , Moyano-Sanchez Ana Maria , Moreno-Moreno Paloma , Rebollo-Roman Angel , Galvez Moreno Maria Angeles

Objective: Flash glucose monitoring (FGM) allows non-invasive glucose level assessment. Our objective was to describe the characteristics of these patients and their glycemic control expressed as HbA1c and times in range. Methods and patientsObservational longitudinal clinical study between January 2021 and December 2021 in patients with DM1 between 14 and 18 years. Results 95 patients included. Mean age: 16.64 ± 1.25 years, with a mean DM evolution time of 6.46 ± 3....

ea0081ep693 | Pituitary and Neuroendocrinology | ECE2022

Influence of Desmopressin treatment in patients undergoing surgery for cushing’s disease

Moreno-Moreno Paloma , Rebollo-Roman Angel , Leon-Idougourram Soraya , Teomiro Carlos Manuel Alza s , Angeles Galvez-Moreno Maria

Objective: ACTH-secreting pituitary tumors (ACTHomas) express vasopressin (AVP) receptors. AVP receptors are also present in other types of cancer, exerting different effects on tumor growth depending on the receptor subtype. AVP type 1 receptors (V1a and V1b) are associated with stimulation of cell proliferation, AVP receptor type 2 (V2r) is associated with antiproliferative effects. Desmopressin (DAVP) is a synthetic analog of AVP that acts as a selective agonist for V2r, wh...

ea0090ep57 | Adrenal and Cardiovascular Endocrinology | ECE2023

Adrenal venous sampling in patients with hyperaldosteronism

Moyano-Sanchez Ana Maria , Rebollo-Roman Angel , Serrano Laguna Ma del Carmen , Moreno-Moreno Paloma , Galvez Moreno Maria Angeles

Objective: Adrenal venous sampling (AVS) is a reliable procedure to differentiate if in patients with primary aldosteronism (PA) aldosterone production is unilateral or bilateral and guide treatment of these patients. Our objective was to describe their characteristics and the outcomes of the AVS.Methods and patients: Observational longitudinal clinical study between July 2020 and November 2022 in patients who underwent AVS in our Hospital.<p class="...